News and Analysis | Published:

Small molecules against RNA targets attract big backers

Nature Reviews Drug Discovery volume 16, pages 813815 (2017) | Download Citation

Novartis, Merck, Pfizer and biotech entrepreneurs have started working on small-molecule drugs that act on an assortment of RNA targets, hoping to unlock once undruggable targets and new biology.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

About this article

Publication history




  1. Search for Asher Mullard in:

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing